Synthetic hepatitis C polypeptide and methods of making and using same
US10188726B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 27, 2016 |
| Grant date | Jan 29, 2019 |
| Priority date | — |
| Expiry date | Oct 27, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/24234
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Synthetic representative HCV subtypes, including a 1a and 1b genome, dubbed Bole1a and Bole1b, are provided using an inventive method of Bayesian phylogenetic tree analysis, ancestral sequence reconstruction and covariance analysis. Bole1a branches centrally among 390 full-genome sequences used in its design, a carefully curated 143 sequence full-genome dataset, and separate genomic regions including an independent set of 214 E1E2 sequences from a Baltimore cohort. Bole1a is phylogenetically representative of widely circulating strains. Full genome non-synonymous diversity comparison and 9-mer peptide coverage analysis showed that Bole1a is able to provide more coverage (94% and 78% respectively) than any other sequence in the dataset including H77, a traditional reference sequence. Bole1a also provides unsurpassed epitope coverage when compared to all known T cell epitopes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.